Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis

Authors

Sabrina Paganoni, Harvard University
Timothy M. Miller, Washington University School of Medicine in St. Louis
et al

Journal

The New England Journal of Medicine

Publication Date

2020

Volume

383

Issue

10

First Page

919

Last Page

930

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1916945

Rights and Permissions

Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020 Sep 3;383(10):919-930. doi: 10.1056/NEJMoa1916945

Recommended Citation

Paganoni, Sabrina; Miller, Timothy M.; and al, et, "Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis." The New England Journal of Medicine. 383, 10. 919 - 930. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/10698